Subcutaneous Biologics Market Size, Share, By Subcutaneous Drug Delivery Systems (Prefilled Syringe, Wearable Injectors, Auto-Injectors, and Drug Reconstitution Delivery Systems), By Application (Crohn’s Disease, Rheumatoid Arthritis, Breast Cancer, Leukemia, Lymphoma, and Psoriasis) and By Region - Trends, Analysis and Forecast till 2034

Subcutaneous Biologics Market was valued at USD 205.2 billion in 2024 and is projected to grow at a CAGR of 12.3% to reach USD 656.3 billion by 2034.

Biologic is also called as biopharmaceutical; it is a complex therapeutic product produced by a biological process. Biologics such as vaccines, body proteins, somatic cells, plasma, and blood-derived products. Biologics market has a lucrative opportunity due to its broad application. Most of the biologics are given intravenously. In the past years, various biologics has given subcutaneously. This route of administration has important advantages over the intravenous mode of administration such as it doesn’t require any skilled person for drug administration and allow at-home drug delivery, hence it reduces time, medicine cost and increased therapy compliance. Due to its above-mentioned facts, subcutaneous mode of administration is highly-effective while administrating proteins, peptides, vaccines, antibodies, and another complex molecule. In turn, it is expected to fuel the subcutaneous biologics market growth over the forecast period.

                     For More Report Details, Download Free Sample PDF

Prevalence of diseases such as cancer, tumors etc.

As of now, the prevalence of diseases such as cancer, tumors, and autoimmune diseases followed by increasing research & development activity on biologics is anticipated to boost the subcutaneous biologics market for over the forecast period.

Additionally, increasing focus on the biologic products is a key factor fueling the overall market growth. In addition to this, government initiatives for the awareness of vaccines in emerging countries are likely to propel the growth of the subcutaneous biologics market during the forecast period.

Subcutaneous Biologics market is segmented based on Subcutaneous Drug Delivery System, Application and region.

On the basis of Subcutaneous Drug Delivery System, the Subcutaneous Biologics market is segmented into Prefilled Syringe, Wearable Injectors, Auto-Injectors, and Drug Reconstitution Delivery Systems. On the basis of Application, the target market is segmented into Crohn’s Disease, Rheumatoid Arthritis, Breast Cancer, Leukemia, Lymphoma, and Psoriasis.

Subcutaneous Biologics Market Regional Insights

On region the Subcutaneous Biologics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account major market share as compared to that of other regions owing to increasing presence of biopharmaceutical industries with increasing demand of precision medicine.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Subcutaneous Biologics Market report based on Subcutaneous Drug Delivery System, Application and region:

Subcutaneous Biologics Market, By Subcutaneous Drug Delivery System:

• Prefilled Syringe
• Wearable Injectors
• Auto-Injectors
• Drug Reconstitution Delivery Systems

Subcutaneous Biologics Market, By Application:

• Crohn’s Disease
• Rheumatoid Arthritis
• Breast Cancer
• Leukemia
• Lymphoma
• Psoriasis

Subcutaneous Biologics Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Key players operating in the market of subcutaneous biologics include AbbVie, Inc., Biogen Idec, F. Hoffmann-La, Takeda Pharmaceutical Company Ltd., Roche AG, Genentech Inc., Amgen, Inc., Eisai, Inc., Pfizer Ltd., and Bristol-Myers Squibb.

• AbbVie, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Biogen Idec
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• F. Hoffmann-La
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Takeda Pharmaceutical Company Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Roche AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Genentech Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Amgen, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Eisai, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Pfizer Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bristol-Myers Squibb
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

“*” marked represents similar segmentation in other categories in the respective section